GS has given back last week's gains and then some, dropping nearly 2% to $928.74 as the bullish options sentiment that defined the prior note has quietly reversed course.
Seven days ago this column noted that the put/call ratio had hit a 52-week low — the most aggressively bullish options stance Goldman had seen in a year. That setup has unwound. The PCR has climbed to 0.915, now running about 1.6 standard deviations above its 20-day mean of 0.872. Options traders have rotated from chasing calls to buying protection, flipping the positioning story from bullish to cautious in the space of a week. The borrow market adds no meaningful signal here: availability remains extraordinarily loose at over 6,300%, and the cost to borrow has actually eased to 0.31% — its lowest level in the 30-day window. Short interest ticked up fractionally to 2.2% of the free float, barely changed on the week and still the same low absolute level it has been for months. The short side is not the story; the options shift is.
The price action fits the broader sector tone. Close peers MS and JEF both fell on the week, down 1.2% and 2.7% respectively. and dropped harder — off 5.2% and 5.1% — suggesting the pressure is broad-based rather than Goldman-specific. was the outlier, adding 2.2% over the same period. GS's 1.8% weekly decline sits roughly in the middle of its peer group, which offers some context: this looks less like a stock-specific sell-off and more like a sector repricing.
The Street remains broadly constructive but has become more selective on valuation. After the April 13 Q1 print, analysts clustered around targets of $930–$1,050. Citi's Keith Horowitz raised his target to $930 on May 8 — effectively spot — while maintaining a Neutral rating, a signal that at least one major firm sees the stock as fairly valued at these levels rather than cheap. BofA and Wells Fargo both held Buy and Overweight ratings respectively through April but trimmed targets, with BofA at $1,050 and Wells at $1,000. The mean target sits above current levels, implying the consensus still sees upside from here, but the stock has pulled back from $948 last week toward the lower end of the neutral-rated price range. The P/E has eased to 15.1x and the P/B to 2.44x — both compressing modestly over the past week. GS's dividend score ranks in the 93rd percentile, a factor that continues to attract passive and income-oriented holders; the top three institutional holders — Vanguard, BlackRock, and State Street — collectively own close to 24% of shares outstanding.
On the insider side, CFO Denis Coleman sold roughly $6.7m worth of stock on May 14 across four tranches priced between $972 and $975. Chief Legal Officer Kathryn Ruemmler sold a combined $4.7m on May 6 at prices around $934–$941. Both sales were executed above current levels, which is worth noting given the subsequent pullback. Neither sale is outsized relative to the firm's float, and trade significance scores are low, but the pattern of executive monetisation near multi-week highs adds a modest data point to the cautious tilt now visible in options.
Q2 results are due July 14. Between now and then, the key variable is whether the investment banking pipeline — specifically the IPO calendar and M&A deal flow — firms up enough to push the stock back through the analyst target cluster. The recent note flagged that post-provision revenue missed and operating expenses rose; the July print will test whether those were transient headwinds or something stickier.
See the live data behind this article on ORTEX.
Open GS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
